Involvement of proteasome β1i subunit, LMP2, on development of uterin leiomyosarcma

Background: Although the majority of smooth muscle neoplasms found in the uterus are benign, uterine leiomyosarcoma is extremely malignant, with high rates of recurrence and metastasis. The development of gynecologic tumors is often correlated with secretion of female hormone; however, the development of human uterine leiomyosarcoma is not substantially correlated with hormonal conditions, and the risk factors are unclearly understood. Importantly, a diagnostic-biomarker, which distinguishes malignant human uterine leiomyosarcoma from benign tumor leiomyoma is yet to be established. Aims: It is necessary to analyze risk factors associated with human uterine leiomyosarcoma, in order to establish a diagnostic-biomarker and a clinical treatment method. Patients and Methods: Histology and Immunofluorescence Staining: Uteri obtained from LMP2–/– mice or its parental mice (C57BL/6 mice) were fixed in 10% buffered formalin, incubated in 4% paraformaldehyde for 8 hours, and embedded in paraffin. Tissue sections (5 μm) were prepared and stained with H&E for routine histological examination or were processed further for immunofluorescence staining with appropriate antidodies. Furthermore, a total of 101 patients between 32 and 83 years of age and diagnosed as having smooth muscle tumors of the uterus were selected from pathological files. Immunohistochemistry staining for LMP2 was performed on serial human uterine leiomyosarcoma, leiomyoma and myometrium sections. Results: Homozygous deficient mice for a proteasome β1i subunit, LMP2 spontaneously develop uterine leiomyosarcoma, with a disease prevalence of ~40% by 14 months of age. Defective LMP2 expression in human uterine leiomyosarcoma was demonstrated, but present in human leiomyoma and myometrium. Conclusions: Loss in LMP2 expression may be one of the risk factors for human uterine leiomyosarcoma. LMP2 may be a potential diagnostic-biomarker and targeted-molecule for a new therapeutic approach.

[1]  J. Lees,et al.  Rb regulates fate choice and lineage commitment in vivo , 2010, Nature.

[2]  D. Timmerman,et al.  Clinical management of uterine sarcomas. , 2009, The Lancet. Oncology.

[3]  B. Slomovitz,et al.  Uterine sarcoma 2008 , 2008, Current oncology reports.

[4]  L. Linares,et al.  The proteasome regulates HIV-1 transcription by both proteolytic and nonproteolytic mechanisms. , 2007, Molecular cell.

[5]  Eero Pukkala,et al.  Analysis of fumarate hydratase mutations in a population‐based series of early onset uterine leiomyosarcoma patients , 2006, International journal of cancer.

[6]  Takuma Hayashi,et al.  The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-γ inducibility of TAP1 and LMP2 , 2006, Oncogene.

[7]  M. Miettinen,et al.  Evaluation of biological potential of smooth muscle tumours , 2006, Histopathology.

[8]  K. Hsu,et al.  Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma. , 2006, Gynecologic oncology.

[9]  S. Topuz,et al.  The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study. , 2005, Gynecologic oncology.

[10]  J. Maller,et al.  A Centrosomal Localization Signal in Cyclin E Required for Cdk2-Independent S Phase Entry , 2004, Science.

[11]  Hai-yan Lin,et al.  Expression of Proteasome Subunits Low Molecular Mass Polypeptide (LMP) 2 and LMP7 in the Endometrium and Placenta of Rhesus Monkey (Macaca mulatta) During Early Pregnancy1 , 2004, Biology of reproduction.

[12]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[13]  K. Dusenbery,et al.  Limitations of adjuvant radiotherapy for uterine sarcomas spread beyond the uterus. , 2004, Gynecologic oncology.

[14]  M. Zhan,et al.  Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. , 2004, Gynecologic oncology.

[15]  A. Celada,et al.  Regulation of murine Tap1 and Lmp2 genes in macrophages by interferon gamma is mediated by STAT1 and IRF-1 , 2004, Genes and Immunity.

[16]  N. Matsumura,et al.  PEP-19 overexpression in human uterine leiomyoma. , 2003, Molecular human reproduction.

[17]  J. Felix,et al.  The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus. , 2003, Gynecologic oncology.

[18]  S. Dobbs,et al.  Soft tissue, pelvic, and urinary bladder leiomyosarcoma as second neoplasm following hereditary retinoblastoma , 2003, Journal of clinical pathology.

[19]  中島 千種.  A Role of Interferon-γ(IFN-γ) in Tumor Immunity : T Cells with the Capacity to Reject Tumor Cells Are Generated But Fail to Migrate to Tumor Sites in IFN-γ-deficient Mice , 2002 .

[20]  Takuma Hayashi,et al.  Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice. , 2002, Cancer research.

[21]  R. Schreiber,et al.  Cancer immunoediting: from immuno- surveillance to tumor escape , 2002 .

[22]  B. Woda,et al.  A high-grade primary leiomyosarcoma of the bladder in a survivor of retinoblastoma. , 2001, Archives of pathology & laboratory medicine.

[23]  S. Elledge,et al.  Phosphorylation-Dependent Ubiquitination of Cyclin E by the SCFFbw7 Ubiquitin Ligase , 2001, Science.

[24]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[25]  H. Fujiwara,et al.  A Role of Interferon-γ (IFN-γ) in Tumor Immunity: T Cells with the Capacity to Reject Tumor Cells Are Generated But Fail to Migrate to Tumor Sitesin IFN-γ-deficient Mice , 2001 .

[26]  K. Schwarz,et al.  Interferon-γ inducible exchanges of 20S proteasome active site subunits: Why? , 2001 .

[27]  N. Shimbara,et al.  Tissue and cell distribution of a mammalian proteasomal ATPase, MSS1, and its complex formation with the basal transcription factors. , 2000, Biochemical and biophysical research communications.

[28]  C. Sherr.  The Pezcoller lecture: cancer cell cycles revisited. , 2000, Cancer research.

[29]  B. Seliger,et al.  Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin , 2000, Bone Marrow Transplantation.

[30]  T. Nikaido,et al.  Possible role of calponin h1 as a tumor suppressor in human uterine leiomyosarcoma. , 1999, Journal of the National Cancer Institute.

[31]  T. Maniatis,et al.  A ubiquitin ligase complex essential for the NF-kappaB, Wnt/Wingless, and Hedgehog signaling pathways. , 1999, Genes & development.

[32]  T. Nikaido,et al.  Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas. , 1999, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[33]  T. Nikaido,et al.  Reduced expression of calponin h1 in leiomyosarcoma of the uterus. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[34]  T. Taniguchi,et al.  Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage , 1996, Nature.

[35]  S. Tonegawa,et al.  Altered peptidase and viral-specific T cell response in LMP2 mutant mice. , 1994, Immunity.

[36]  A. Goldberg,et al.  Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. , 1993, Nature.

[37]  M Kitagawa,et al.  Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2 , 1993, Science.

[38]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[39]  M. Baggish.  Mesenchymal tumors of the uterus. , 1974, Clinical obstetrics and gynecology.

[40]  E. Aguilera,et al.  Uterine sarcoma , 2022 .

[41]  Ralph,et al.  A Clinicopathologic Study , 2006 .